As part of our continued expansion, Only Medics have relocated to a new larger UK office, having outgrown our previous office. The new office is over double the size of the previous UK office, allowing Only Medics to continue growing to fit your future needs. Our new office is located at: 1st Floor 33 Blagrave
Only Medics will be attending this year’s BrAPP Annual Symposium on 7th March 2013 in Royal College of Pathologists. The conference will start at 9am, and will conclude at 5pm with the BrAPP AGM for BrAPP members. The conference offers attendees the chance to opportunity to network with fellow pharmaceutical physicians, speakers and other colleagues.
Warner Chilcott has announced that their fourth-quarter net income grew 37.8%, although pharmaceutical sales were hit by the impact of generic competition for their osteoporosis drug, Actonel. The organisation’s net income increased to $124 million, or 49 cents per share, up from $90 million, or 36 cents per share. The company’s revenue dropped 5%, to
CROMSOURCE, which was formed roughly two years ago as a result of the acquisition of MSOURCE by CROM, has combined it’s presence in Poland with a new office in Warsaw. When CROM acquired MSOURCE, the latter contract research organisation (CRO) had been internationally active since 1994. Dr Oriana Zerbini, chief executive officer of CROMSOURCE, commented
Roche has teamed up with Chiasma to develop and market Octreolin, Chiasma’s investigational treatment for growth hormone disorders. Octreolin is oral form of the peptide octreotide, a somatostatin analogue which is currently only commercially available by injection and is marketed by Novartis as Sandostatin. The drug is currently in a Phase III clinical trial for
Astellas and Aveo Pharmaceuticals have announced that the overall survival (OS) data for their kidney cancer drug, tivozanib, which demonstrates that it matches a key competitor. Two-year data from the TIVO-1 clinical study shows that there is no statistically significant difference in the overall survival rate for tivozanib and Bayer/Onyx’s Nexavar, with both treatments providing
Sanofi’s fourth quarter earnings have been hit by generics, although the majority of the patent cliff is now behind the French drugmaker, who anticipate a return to growth in the second half of 2013. Business net income, which excludes items, dropped 27.1% to 1.57 billion euros (at constant exchange rates), mainly as a result of
Takeda Pharmaceuticals have revealed reasonable financial results for the first nine months of their fiscal year, regardless of the major drop in sales of their diabetes drug, Actos. Japan’s largest drugmaker’s net income for the April-December period dropped 13.5% to 138.91 billion (around $1.51 billion), however sales increased by 5.5% to 1.189 trillion yen. Actos
Pfizer have released a reasonable set of financials despite the effects of generic competition to their cholesterol blockbuster drug, Lipitor. Fourth-quarter net income soared to $6.32 billion, up from $1.44 billion in the like-for-like quarter of the previous year. The net income was boosted by the sale of their nutrition business to Nestle for $11.85
Watson Pharmaceuticals, the third-biggest generics drugmaker, have changed their name to Actavis and set out their growth plans. The company initially revealed intentions to change their name last year, succeeding the acquisition of the Actavis Group. The company has begun a multi-year rebranding campaign that will guide the transition of their facilities, operations and commercial
